4756 Vol. 9, 4756–4760, October 15, 2003 Clinical Cancer Research A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Rofecoxib, a Selective Cyclooxygenase-2 Inhibitor, on Rectal Polyps in Familial Adenomatous Polyposis Patients Tetsuro Higuchi, Takeo Iwama, Keigo Yoshinaga, cantly decreased the number and size of rectal polyps in Masahiro Toyooka, Makoto M. Taketo, and familial adenomatous polyposis patients. Kenichi Sugihara1 Department of Digestive Surgery, Graduate School, Tokyo Medical INTRODUCTION and Dental University, Tokyo 113-8519 [T. H., K. Y, M. T., K. S.]; FAP2 is an autosomal dominant disease caused by a germ- Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501 [M. M. T.]; and Department of Surgery, line mutation in the APC gene located at chromosome 5q21 Kyoundo Hospital, Sasaki Institute, Tokyo 101-0062 [T. I.], Japan (1–3). Patients with FAP develop hundreds to thousands of adenomatous polyps, and they are at a nearly 100% risk of colorectal cancer (4). Management includes prophylactic proc- ABSTRACT tocolectomy or colectomy followed by sigmoidoscopic surveil- Purpose: The aim of this study was to examine the effect lance and rectal polypectomy. Studies of FAP may contribute to of a specific cyclooxygenase-2 inhibitor, rofecoxib, on rectal the prevention of colorectal cancer in patients with not only in polyps in familial adenomatous polyposis patients. FAP but also sporadic polyps. Experimental Design: This was a randomized, double- Epidemiological studies have shown that regular use of blind, placebo-controlled study of the efficacy and safety of aspirin-like drugs or NSAIDs reduces the incidence of and rofecoxib in the rectum. Initially, 21 patients were assigned mortality from sporadic adenoma and colorectal cancer (5–7). randomly in a 1:1 ratio to receive either 25 mg rofecoxib Recent studies in two large randomized, double-blind clinical once a day or a placebo p.o. for 9 months. Patients under- trials have demonstrated that aspirin reduces the risk of recur- went endoscopy at the beginning of the study and then every rent adenomas among patients with a history of colorectal 3 months thereafter. We reviewed the videotapes to measure cancer or adenomas (8, 9). There are case reports indicating that the number and size of polyps in the same area throughout adenomatous polyps may regress in FAP patients who receive the study period in each individual patient. sulindac, an NSAID (10, 11). In small, randomized, placebo- Results: The polyp number, measured as the percentage controlled trials, sulindac treatment produced a significant re- of change from the baseline values, was significantly de- gression of colorectal adenomas in patients with FAP (12–14). creased in the rofecoxib group at 3, 6, and 9 months. At 9 However, long-term use of conventional NSAIDs for cancer months, the polyp number in the rofecoxib group decreased prevention is hampered by their strong gastrointestinal toxicity by 6.8% from the baseline values, whereas that in the pla- cebo group increased by 3.1%. The 9.9% difference between (15). In FAP, the chemopreventive effects of NSAIDs appear to the rofecoxib and placebo groups was statistically significant be through their inhibition of COX-2 (16, 17). A COX-2- At 9 months, the rofecoxib group showed a selective inhibitor, celecoxib, has been shown to decrease polyp .(0.004 ؍ P) significant reduction from the baseline in polyp size as com- number and size in chemically induced Apc mutant Min mouse pared with the placebo group (؊16.2% versus 1.5%; P < (18). In a clinical trial with FAP patients, celecoxib has also 0.001). There was no statistically significant increase in the been reported to have moderate efficacy in reduction of colonic incidence of any adverse events in treatment with rofecoxib polyps, at twice the maximum recommended dose for patients with osteoarthritis and rheumatoid arthritis (19). Rofecoxib is a .(0.922 ؍ compared with placebo (P Conclusions: In this study, once-daily treatment with 25 COX-2-specific inhibitor, which has higher selectivity to mg rofecoxib, a cyclooxygenase 2-specific inhibitor, signifi- COX-2 than celecoxib (20). In vivo, rofecoxib has been shown to reduce polyp number and size in the Apc mutant mouse; hence, rofecoxib is a potential chemopreventive agent in ade- noma and colon cancer (21). The aim of this study was to examine the effect of rofecoxib at a clinically approved dose in Received 2/17/03; revised 6/10/03; accepted 6/24/03. the United States and Europe on rectal polyps in FAP patients. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 To whom requests for reprints should be addressed, at Department of Digestive Surgery, Tokyo Medical and Dental University, 1-5-45 2 The abbreviations used are: FAP, familial adenomatous polyposis; Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. Phone: 81-3-5803-5261; APC, adenomatous polyposis coli; NSAID, nonsteroidal anti-inflamma- Fax: 81-3-5803-0139; E-mail: [email protected]. tory drug; COX, cyclooxygenase. Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 2003 American Association for Cancer Research. Clinical Cancer Research 4757 Table 1 Schedule of the study Treatment period Post-treatment period Months Baseline 123456789101112Discontinuation Colonoscopy X X X X X X Gastroduodenoscopy X X X X Physical examination X XXXXXXXXX X X X X Blood pressure, body weight X XXXX X XX X Laboratory tests X XXXX X XX X MATERIALS AND METHODS were excluded from the efficacy analysis, although they were Patients. This was a randomized, double-blind, placebo- included in the safety analysis. Namely, 21 patients were in- controlled study of the efficacy and safety of rofecoxib in cluded in the safety analysis, and 16 patients were included in reducing percentage area of disease in the rectum, and in the efficacy analysis. The following are reasons for 5 patients reducing the extent of rectal polyposis. Twenty-one patients excluded from the efficacy analysis. One patient had no avail- with FAP were enrolled in the study (11 males and 10 able endoscopic data before (at the baseline) the treatment, 1 had females, median age 30 years), recruited during their routine a history of total gastrectomy (difficult to evaluate the efficacy clinical follow-up at Kyoundo Hospital Sasaki Institute, because of potential effects on drug absorption), 1 had used (Tokyo, Japan) and Tokyo Medical and Dental University. another NSAID for a treatment of an adverse effect, 1 discon- Patients diagnosed as FAP on the basis of having at least 100 tinued within a month because of an adverse effect (gastroen- colorectal polyps at endoscopy and/or in colectomy speci- teritis), and another requested to discontinue the drug treatment mens were eligible if they had five or more rectal polyps of because of adverse effect (redness of legs and gingival pain). Ն 2 mm in diameter when assessed endoscopically, and if the Endoscopy. Videotaped colonoscopy with Olympus rectal region was still intact. Accordingly, patients with at- flexible colonoscopes was performed before the beginning of tenuated FAP were not included. The age distribution of the study therapy (the baseline), every 3 months during the enrolled patients was 19–55 years. No patients were tested treatment, and at 3 months after the treatment. An intestinal for APC mutations. Subjects included 13 postcolectomy pa- enema was given as a pretreatment with 200–500 ml saline tients. Although average time postcolectomy was 87 months, solution. The indigocarmine spraying method was used dur- we did not exclude patients within 2 years after operations. ing the endoscopy so that no small or flat adenomas were The following were the reasons for exclusion from the overlooked. At the baseline endoscopy, the largest rectal study: patients required colectomy for dense adenomas, had polyp was identified as a landmark, and the diameters of this Ͼ10-mm adenoma or malignant disease, use of an NSAID or polyp as well as four more vicinal polyps were determined aspirin within 1 month preceding the study, history of peptic using the endoscopic ruler. The endoscopic examinations ulcers or gastrointestinal hemorrhage, history of severe side- were videotaped, and a series of photographs were taken of effects by NSAIDs, clinically significant abnormal results in the area near the landmark polyp. These photographs were laboratory data, history of active bacterial infection, drug hy- used for quantitative measurements of the number and size of persensitivity, absence of the use of effective birth control in polyps. Follow-up gastroduodenoscopic examinations were women of childbearing age, or pregnancy. performed at the baseline, 9 months, and 12 months, respec- The study was approved by the Institutional Review Boards of the investigative sites, and written informed consent tively. was obtained from all of the patients. Because rofecoxib is not Clinical Assessment. For each patient, the same investi- yet approved for clinical use in Japan, the protocol was submit- gator who performed the endoscopy reviewed the videotapes ted to and approved by Japanese Ministry of Health and Wel- and prepared the video-photographs of polyps of the same area fare. According to the protocol, 21 patients were initially as- for evaluation throughout the study period. Independent endos- signed randomly in a 1:1 ratio to receive p.o. either 25 mg copists assessed the number and size of polyps based on these rofecoxib (Merck and Co., Inc.) or an identical-appearing pla- video-photographs. The efficacy of the treatment was assessed cebo once daily for 9 months. The rofecoxib dose of 25 mg was by separate investigators from those who performed the endos- selected on the basis of the standard therapy for osteoarthritis.